PsychoGenics Announces Positive Phase-IIa For Its First-in-Class Partial 5-HT1A - 5-HT1B Receptor Agonist In ADHD
PsychoGenics Inc. announced positive data from its randomized, placebo controlled, multicenter, Phase IIa trial of eltoprazine, the company’s lead partial 5-HT1A - 5-HT1B receptor agonist, in adult patients with Attention Deficit/ Hyperactivity Disorder (ADHD).
